Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia

Inclusion Criteria: 1. Men and women greater than or equal to 18 years of age; 2. Baseline platelet count \<50×10\^9/L; 3. End-stage liver disease, including acute-on-chronic liver failure, acute decompensation of liver cirrhosis, chronic liver failure; 4. Women of childbearing potential must agree to use a highly effective method of contraception from the beginning of Baseline Visit until the end of treatment (includes implantable contraception, injectable contraception, hormonal combination contraception \[including vaginal rings\], intra-uterine devices or vasectomy). The barrier contraception with or without spermicide alone, double barrier contraception and oral contraceptives are inadequate; 5. Subject is able to understand the study and willing to follow the protocol and sign informed consent voluntarily before Baseline Visit; 6. Subject meet the criteria according to the opinion of the researchers. Exclusion Criteria: 1. Subject has a history of arterial or venous thrombosis within the previous 6 months of baseline; 2. Known portal vein blood flow velocity rate \<10 cm/second or previous occurrence of a portal vein thrombosis within 6 months of Baseline; 3. Known any history of primary blood (e.g, immune thrombocytopenia, myelodysplastic syndrome, aplastic anemia); 4. Subject has a known medical history of genetic prothrombotic syndromes (e.g, Factor V Leiden prothrombin G20210A, antithrombin III (AT III) deficiency); 5. Subject has a recent history (within the previous 6 months) of significant cardiovascular diseases (e.g., exacerbation of congestive heart failure, arrhythmias known to increase the risk of thromboembolic events \[e.g. atrial fibrillation\], coronary or peripheral artery stent placement or angioplasty, and coronary or peripheral artery bypass grafting); 6. Female subjects who are lactating or pregnant at the Baseline Visit (as documented by a positive serum beta-human chorionic gonadotropin \[β-hCG\] test with a minimum sensitivity of 25 IU/L or equivalent units of β-hCG) or are planning to become pregnant during the study; 7. The subject has a hypersensitivity to Avatrombopag or any of its excipients; 8. Subjects with drug-induced thrombocytopenia; 9. Subjects whose Life expectation ≤6 months; 10. Subject with a current malignancy; 11. Subjects with HIV infection; 12. At screening, active infection was not effectively controlled by systemic antibiotic therapy; 13. The Investigator believe that any accompanying medical history may affect the safety of the subjects to complete the study; 14. The Investigator believe that there are any other factors that are not suitable for inclusion or affect participation or completion of the study; 15. Subject is enrolled in another clinical study with any investigational drug or device within previous 30 days of the Baseline Visit, but are allowed to participate in observational studies.